Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib.
Abhishek TripathiJeffrey G SupkoKathryn P GrayZachary J MelnickMeredith M ReganMary-Ellen TaplinAtish D ChoudhuryMark M PomerantzJoaquim BellmuntChanning YuZijie SunSandy SrinivasPhilip W KantoffChristopher J SweeneyLauren C HarshmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Concurrent administration of enzalutamide and crizotinib resulted in a clinically significant 74% decrease in systemic crizotinib exposure. Further investigation of this combination in CRPC is not planned. Our results highlight the importance of evaluating pharmacokinetics interactions when evaluating novel combination strategies in CRPC.